Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13486530 | 0.80 | HPSE (0.52) | MAOBL3MBTL1PPARGESR1ALDH1A1 | |
| SCHEMBL9423156 | 0.77 | LMNA (0.43) | MAOBLMNAL3MBTL1PPARGALDH1A1 | |
| SCHEMBL9423154 | 0.77 | LMNA (0.43) | MAOBLMNAL3MBTL1PPARGALDH1A1 | |
| SCHEMBL14608877 | 0.73 | MAOB (0.46) | MAOBLMNAL3MBTL1PPARGKMT2A | |
| SCHEMBL8916232 | 0.71 | ALDH1A1 (0.46) | LMNAESR1KMT2AMEN1ALDH1A1 | |
| SCHEMBL23796824 | 0.70 | MEN1 (0.60) | MAOBLMNAL3MBTL1PPARGKMT2A | |
| SCHEMBL340618 | 0.70 | MAOB (0.67) | MAOBLMNAL3MBTL1PPARGESR1 | |
| SCHEMBL340937 | 0.70 | HTT (0.69) | L3MBTL1KMT2AMEN1HSP90AA1ALDH1A1 | |
| SCHEMBL112672 | 0.69 | MEN1 (0.59) | MAOBLMNAL3MBTL1PPARGKMT2A | |
| SCHEMBL4400182 | 0.69 | KMT2A (0.67) | MAOBLMNAL3MBTL1PPARGKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029761-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | FAS SECURED CREDITORS HOLDCO, LLC | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029761-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | NR1H4, CYP3A4, CYP4A11 | MAOB 1450/4885LMNA 3460/4885L3MBTL1 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.